Literature DB >> 32299014

Recent advances in atopic dermatitis.

Kangmo Ahn1, Byung Eui Kim2, Jihyun Kim1, Donald Ym Leung3.   

Abstract

The prevalence and disease burden of atopic dermatitis (AD) is substantial. AD causes significant impairment in quality of life. It is also associated with mental disorders as well as cardiovascular diseases. Many factors including race, environment, skin barrier dysfunction, immune regulatory abnormalities, and microbiome have been reported to affect the pathophysiology of AD. A variety of cell types including Th2, Th17, Th22, and type 2 innate lymphoid cells contribute to AD. Cytokines from these immune cells cause abnormal epidermal differentiation and skin barrier dysfunction. Moreover, microbial dysbiosis and deficiency of antimicrobial peptides result in Staphylococcus aureus infection. Recently, new drugs have been successfully launched to target polarized immune pathways that lead to moderate-to-severe AD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32299014      PMCID: PMC7554175          DOI: 10.1016/j.coi.2020.02.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  53 in total

1.  The microbiome and allergic diseases: A struggle between good and bad microbes.

Authors:  Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2019-01-09       Impact factor: 6.347

2.  IL-10-Producing Regulatory B Cells Are Decreased in Patients with Atopic Dermatitis.

Authors:  Yuki Yoshihara; Yozo Ishiuji; Ayumi Yoshizaki; Miki Kurita; Mitsuha Hayashi; Takaoki Ishiji; Hidemi Nakagawa; Akihiko Asahina; Koichi Yanaba
Journal:  J Invest Dermatol       Date:  2018-09-17       Impact factor: 8.551

3.  The prevalence and persistence of atopic dermatitis in urban United States children.

Authors:  Costner McKenzie; Jonathan I Silverberg
Journal:  Ann Allergy Asthma Immunol       Date:  2019-05-22       Impact factor: 6.347

4.  Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.

Authors:  Eric L Simpson; Jane R Parnes; Dewei She; Sarah Crouch; William Rees; May Mo; René van der Merwe
Journal:  J Am Acad Dermatol       Date:  2018-12-12       Impact factor: 11.527

5.  Pathophysiology of atopic dermatitis: Clinical implications.

Authors:  Jihyun Kim; Byung Eui Kim; Donald Y M Leung
Journal:  Allergy Asthma Proc       Date:  2019-03-01       Impact factor: 2.587

6.  Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.

Authors:  Patrick M Brunner; Ana B Pavel; Saakshi Khattri; Alexandra Leonard; Kunal Malik; Sharon Rose; Shelbi Jim On; Anjali S Vekaria; Claudia Traidl-Hoffmann; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Judilyn Fuentes-Duculan; Xuan Li; Xiuzhong Zheng; Yeriel Estrada; Sandra Garcet; Huei-Chi Wen; Juana Gonzalez; Israel Coats; Inna Cueto; Avidan U Neumann; Mark G Lebwohl; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2018-08-17       Impact factor: 10.793

7.  The Association Between Season of Birth and Atopic Dermatitis in the Northern Hemisphere: A Systematic Review and Meta-Analysis.

Authors:  Monika Calov; Farzad Alinaghi; Carsten Robert Hamann; Jonathan Silverberg; Alexander Egeberg; Jacob Pontoppidan Thyssen
Journal:  J Allergy Clin Immunol Pract       Date:  2019-10-31

Review 8.  Epithelial barrier repair and prevention of allergy.

Authors:  Elena Goleva; Evgeny Berdyshev; Donald Ym Leung
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

9.  Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Authors:  Emma Guttman-Yassky; Patrick M Brunner; Avidan U Neumann; Saakshi Khattri; Ana B Pavel; Kunal Malik; Giselle K Singer; Danielle Baum; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sharon Rose; Shelbi Jim On; Xuan Li; Judilyn Fuentes-Duculan; Yeriel Estrada; Sandra Garcet; Claudia Traidl-Hoffmann; James G Krueger; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2018-01-17       Impact factor: 11.527

10.  Lipid abnormalities in atopic skin are driven by type 2 cytokines.

Authors:  Evgeny Berdyshev; Elena Goleva; Irina Bronova; Nathan Dyjack; Cydney Rios; John Jung; Patricia Taylor; Mingeum Jeong; Clifton F Hall; Brittany N Richers; Kathryn A Norquest; Tao Zheng; Max A Seibold; Donald Ym Leung
Journal:  JCI Insight       Date:  2018-02-22
View more
  12 in total

1.  Vitamin D Inhibits IL-22 Production Through a Repressive Vitamin D Response Element in the il22 Promoter.

Authors:  Daniel V Lopez; Fatima A H Al-Jaberi; Nkerorema D Damas; Brian T Weinert; Urska Pus; Sara Torres-Rusillo; Anders Woetmann; Niels Ødum; Charlotte M Bonefeld; Martin Kongsbak-Wismann; Carsten Geisler
Journal:  Front Immunol       Date:  2021-08-02       Impact factor: 7.561

2.  Acute and subacute oral administration of mycotoxin deoxynivalenol exacerbates the pro-inflammatory and pro-pruritic responses in a mouse model of allergic dermatitis.

Authors:  Ryota Aihara; Toa Ookawara; Ai Morimoto; Naoki Iwashita; Yoshiichi Takagi; Atsushi Miyasaka; Masayo Kushiro; Shiro Miyake; Tomoki Fukuyama
Journal:  Arch Toxicol       Date:  2020-08-19       Impact factor: 5.153

Review 3.  Mast Cell-Specific MRGPRX2: a Key Modulator of Neuro-Immune Interaction in Allergic Diseases.

Authors:  Monica Thapaliya; Chalatip Chompunud Na Ayudhya; Aetas Amponnawarat; Saptarshi Roy; Hydar Ali
Journal:  Curr Allergy Asthma Rep       Date:  2021-01-04       Impact factor: 4.919

Review 4.  Emerging Nanomedicines for the Treatment of Atopic Dermatitis.

Authors:  Khushali Parekh; Tejal A Mehta; Namdev Dhas; Pavan Kumar; Amirali Popat
Journal:  AAPS PharmSciTech       Date:  2021-01-24       Impact factor: 3.246

5.  Particulate matter causes skin barrier dysfunction.

Authors:  Byung Eui Kim; Jihyun Kim; Elena Goleva; Evgeny Berdyshev; Jinyoung Lee; Kathryn A Vang; Un Ha Lee; SongYi Han; Susan Leung; Clifton F Hall; Na-Rae Kim; Irina Bronova; Eu Jin Lee; Hye-Ran Yang; Donald Ym Leung; Kangmo Ahn
Journal:  JCI Insight       Date:  2021-03-08

6.  Impact of environmental factors in predicting daily severity scores of atopic dermatitis.

Authors:  Guillem Hurault; Valentin Delorieux; Young-Min Kim; Kangmo Ahn; Hywel C Williams; Reiko J Tanaka
Journal:  Clin Transl Allergy       Date:  2021-04       Impact factor: 5.871

7.  Interferon-Lambda 1 Inhibits Staphylococcus aureus Colonization in Human Primary Keratinocytes.

Authors:  Xia Wu; Yan Zhao; Ying Gu; Kun Li; Xiaojie Wang; Jianzhong Zhang
Journal:  Front Pharmacol       Date:  2021-03-22       Impact factor: 5.810

Review 8.  Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy.

Authors:  Alyssa Sweeney; Vanitha Sampath; Kari C Nadeau
Journal:  Allergy Asthma Clin Immunol       Date:  2021-03-16       Impact factor: 3.406

9.  Temporal and Spatial Variation of the Skin-Associated Bacteria from Healthy Participants and Atopic Dermatitis Patients.

Authors:  Christopher J Barnes; Maja-Lisa Clausen; Anders Johannes Hansen; Tove Agner; Maria Asplund; Linett Rasmussen; Caroline Meyer Olesen; Yasemin Topal Yüsel; Paal Skytt Andersen; Thomas Litman
Journal:  mSphere       Date:  2022-02-23       Impact factor: 4.389

Review 10.  Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.

Authors:  Thanaporn Ratchataswan; Tina M Banzon; Jacob P Thyssen; Stephan Weidinger; Emma Guttman-Yassky; Wanda Phipatanakul
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.